On Wednesday a Pfizer representative told Endpoints News that the pharma giant had no immediate plans to take any new actions related to the marketing of their blockbuster drug Xeljanz. But it’s not entirely in their hands.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription